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Hereditary Renal
Amyloidosis Associated
With a Novel
Apolipoprotein A-II
Variant
To the Editor: Systemic amyloidosis is characterized
by the extracellular deposition of misfolded proteins as
insoluble amyloid ﬁbrils in various tissues. The familial
forms of amyloidosis (AF) comprise a group of auto-
somal dominant diseases associated with mutations in a
number of genes encoding amyloid precursor proteins.
These diseases collectively exhibit various phenotypes,
including ages of onset, organ involvements, rates
of progression, and prognoses.1,2 Hereditary non-
neuropathic, renal amyloidosis was ﬁrst reported by
Ostertag3,4; since that report, mutations in lysozyme,2
ﬁbrinogen A-a chain,5,6 transthyretin,7 gelsolin,8
apolipoprotein (apo) A-I,4,7 A-II,4 A-IV,9,10 C-II,11 and
C-III12 have been linked to the disease. apoA-II
Amyloidosis (AApoAII) is an exceedingly rare
form of AF; only 3 APOA2 mutations have been
reported in 4 families worldwide. In each case, a
nucleotide replacement at the stop codon of APOA2
resulted in a variant apoA-II with a 21-residue
C-terminal extension, 78Argext21, 78Serext21, and
78Glyext21.13–17
Human apoA-II (77 amino acids, 17 kDa) is expressed
in the liver and is found as a disulﬁde-linked homodimer
in circulation. Nearly all circulatingwild-type apoA-II is
strongly bound to plasma high-density lipoprotein
(HDL) via the unusually large apolar faces of its amphi-
pathic a-helices.18,19 Similar to other exchangeable
apolipoproteins, lipid-bound apoA-II acquires a highly
a-helical structure on HDL. Strong binding to HDL
makes wild-type apoA-II practically nonexchangeable
and protected frommisfolding in vivo.18 However, in the
absence of bound lipids in vitro, apoA-II becomes largely
unfolded and labile to misfolding and proteolysis.18,20
Therefore, a population shift from HDL-bound to
HDL-unbound apolipoprotein is thought to augment
the development of AApoAII amyloidosis.15 Notably,
apoA-II is the most hydrophobic member of the
apolipoprotein family with the highest predicted
propensity to form amyloid.21
Here, we report a family with renal amyloidosis
associated with a novel stop codon mutation in APOA2
and the apoA-II variant, 78Leuext21.
RESULTS
Clinical Presentation
The proband (Figure 1, II-4), a 45-year-old woman, was
seen in the Amyloidosis Center at Boston University
School of Medicine for evaluation. At age 41 years,
she was found to have elevated creatinine at 1.5 mg/
dl. At age 44, she developed bilateral leg swelling,
blood pressure of 240/140, serum creatinine of 10 mg/
dl, and 24-hour proteinuria of 13 g. Soon thereafter,
she was started on hemodialysis. Because of labile
hypertension, she underwent a left nephrectomy
at age 45 years; histological examination revealed
amyloid deposits. A workup was negative for
monoclonal gammopathy or amyloid involvement
of other organs. A bone marrow biopsy and an
abdominal fat pad aspirate were negative for amyloid
deposits. At age 46, she underwent cadaveric renal
transplantation and right nephrectomy; histological
examination again showed renal amyloid deposition.
The posttransplantation course was uncomplicated;
treatment has included CellCept, Prograft, and
prednisone.
Evaluation at 18 months postrenal transplantation
was completely unremarkable; blood pressure was 110/70,
and serum creatinine was normal at 1.1 mg/dl with no
proteinuria. There were no episodes of allograft rejection
or signs of extrarenal organ involvement. At age 54 years,
a fat pad biopsy revealed a small focus of amyloid
deposits. Currently, at age 60, she has evidence of slowly
worsening allograft dysfunction with serum creatinine of
1.8 mg/dl and 24-hour proteinuria of 118 mg. Her blood
pressure is 113/74; she exhibits no signs of extrarenal
involvement.
The father of the proband (Figure 1, I-1), originally
from the Philippines, had a history of hypertension
and died of gastrointestinal bleeding at age 59 years.
The mother (I-2) was of Portuguese descent and had a
history of hypertension and diabetes; she died of
stroke at age 74. Siblings include 3 brothers and 2
sisters; none have a history of renal disease.
The proband has 2 children. The daughter (III-1)
was diagnosed with renal amyloidosis at age 30; her
serum creatinine was 0.9 mg/dl and 24-hour urine
protein measured 2.7 g at disease presentation. She was
started on dialysis at age 36 and underwent cadaveric
renal transplantation at age 39. She has been treated
with CellCept and Prograft, and has had no episodes of
graft rejection. Currently, at age 41, her serum creati-
nine is 1.75 mg/dl, urine protein is below the measur-
able range, and she has no signs of extrarenal
involvement.
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The son (III-2) was diagnosed with renal amyloidosis
at age 33 with serum creatinine of 1.45 mg/dl and 24-
hour proteinuria of 7.4 g. At age 35, he started on
peritoneal dialysis. Currently at age 36, he shows no
sign of extrarenal involvement and is wait-listed for a
cadaveric kidney transplant.
Histological Detection and Immunohistochemical
Typing of Amyloid Deposits
Light microscopy of a renal biopsy sample from the
proband (II-4) showed marked inﬁltration of the
glomeruli by eosinophilic deposits. The interstitium
was spared, with only focal involvement of a few small
vessels (Figure 2a1). Intimately admixed with the
amyloid deposits in the glomeruli were
multinucleated giant cells (GCs), present singly and in
loosely cohesive clusters (Figure 2a2, 2b1-2). The
deposits in the glomeruli and some small vessels
stained strongly positive with Congo red, exhibiting
apple green birefringence under polarized light,
distinctive of amyloid (Figure 2c1-2). The amyloid
deposits were strongly immunoreactive with
polyclonal antihuman apoA-II antibody in the
glomeruli; no involvement of blood vessels or
interstitium was noted (Figure 2d1-2).
A kidney biopsy from the daughter (III-1) demon-
strated similar histological features with large glomer-
ular amyloid deposits. There was no evidence of
peritubular or vascular deposition; multinucleated GCs
were not present in the tissue (data not shown). A fat
pad biopsy sample from the son (III-2) showed Congo
red positivity (data not shown).
Genetic Analyses
Direct DNA sequencing of APOA2 in the proband
demonstrated a heterozygous c.302G>T transversion at
the second nucleotide position of the translation
termination codon in exon 4; this mutation encoded
leucine at position 78 of the mature apoA-II protein.
Elimination of the stop codon resulted in a 21-residue
extension at the C-terminal end of the variant pro-
tein, 78Leuext21 (Figure 2e). No other mutations were
noted in exon 3 or the remainder of exon 4. Both
children of the proband were identiﬁed as carriers
of the mutation; 2 of 5 siblings were found to be
negative (Figure 1, II-1 and II-3).
Analysis of Serum apoA-II Proteins
Sera from the proband and several family members
were analyzed immunoelectrophoretically using a
monoclonal antihuman apoA-II antibody. Under
nonreducing conditions, various-sized immunoreactive
bands occurred at positions on the blot corresponding
to molecular weights of 15 to 21 kDa, consistent with
the dimeric forms of apoA-II (Figure 3a). In sera from
the proband and her affected children, protein bands
corresponding to wild-type homodimer, wild-type
and variant heterodimer, and variant homodimer
apoA-II were noted. Conversely, only 1 band
corresponding to wild-type homodimer was observed
in unaffected family members. In the 8- to 10-kDa
range, less abundant immunoreactive bands were
observed in all sera indicative of monomeric apoA-II
(Figure 3a, bottom panel). Under reducing conditions,
sera from affected members demonstrated 2 bands in
the 8- to 10-kDa region, suggesting the presence of
wild-type and variant apoA-II monomers (Figure 3b).
A single immunoreactive band of 8 kDa consistent
with wild-type apoA-II monomer was observed in sera
from unaffected members. Of note, serum from the
daughter of the proband (III-1) featured wild-type
apoA-II dimers and monomers of slightly different
sizes compared with those identiﬁed in other affected
members; no molecular weight differences in variant
apoA-II species were demonstrated.
Identiﬁcation of apoA-II in Amyloid Fibrils
Immunoelectrophoretic analysis of amyloid ﬁbrils
extracted from proband kidney tissue showed immu-
noreactive bands at positions similar to those observed
in serum (Figure 4, lane II-4S) and consistent with
dimeric and monomeric apoA-II. Under reducing and
nonreducing conditions, a highly abundant w21-kDa
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Figure 1. Family pedigree. Individuals with renal amyloidosis and the
apoA-II 78Leuext21 mutation are indicated by solid black symbols;
the arrow denotes the proband. Family members negative for
apoA-II 78Leuext21 mutation are shown as solid gray symbols, and
those who were not genotyped are indicated by white symbols.
Ages at the time of this report or death (indicated by diagonal line)
are shown beneath each symbol.
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Figure 2. Proband (II-4) histological and genetic analyses. (a1) Light microscopy of renal parenchyma, showing marked inﬁltration of glomeruli
by eosinophilic deposits (hematoxylin and eosin stain; original magniﬁcation, 100). (a2) Enlarged view of boxed area in a1 panel. Clusters of
multinucleated giant cells (indicated with arrows) intimately admixed with eosinophilic deposits are shown (hematoxylin and eosin stain;
original magniﬁcation, 600). (b1) Multinucleated giant cells are shown randomly dispersed throughout the glomeruli (periodic acidSchiff
stain; original magniﬁcation, 100). (b2) Enlarged view of boxed area in b1 panel showing multinucleated giant cells (indicated with arrows) in a
glomerulus (periodic acid–Schiff stain; original magniﬁcation, 400). (c1) Congo redpositive amyloid deposits viewed by standard light mi-
croscopy (original magniﬁcation, 100). (c2) Polarized light view of c1 section demonstrating “apple”-green birefringent property of Congo
redpositive amyloid deposits (original magniﬁcation, 100). (d1,d2) Immunohistochemistry with polyclonal human apoA-II antibody demon-
strates strong positive immunoreactivity in the glomeruli (original magniﬁcations, 40 and 100, respectively). No positive staining with an-
tibodies to Ig k or l light chains, amyloid A, transthyretin, or apoA-I were demonstrated (data not shown). (Continued)
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protein, indicative of variant homodimer (Figure 4, lane
II-4f), was observed, along with 2 less intense and
slightly lower sized forms of apoA-II (Figure 4, lane
II-4F). Bands with approximate molecular weights of
6kDa, 8kDa, and 10kDa were suggestive of
monomeric apoA-II (Figure 4, lane II-4F).
Mass Spectral Characterization of Amyloid
Fibrils
Amyloid ﬁbrils were electrophoresed under reducing
conditions; 3 gel slices in the areas corresponding to the
6 kDa, 8 kDa, and 10 kDa bands observed on the
immunoblot (Figure 4, asterisk [*]), were excised and
subjected to mass spectral analyses. In each band, the
most abundant peptides represented apoA-II protein;
the number of identiﬁed apoA-II spectra was 137, 109,
and 61, respectively (Figure 5a). Furthermore, peptides
representing the 21-residue C-terminal extension of
variant apoA-II were found, with greatest abundance
in the 6-kDa compared to the 8- and 10-kDa bands (73
vs. 58 and 30 spectra, respectively). Peptides spanning
100% of the apoA-II variant sequence were identiﬁed
in the 10-kDa and, surprisingly, in the 6-kDa bands;
93% sequence coverage was determined in the 8-kDa
band (Figure 5b).
Aggregation Propensity Predictions and Sec-
ondary Structure of the apoA-II Variants
The aggregation propensity of 78Leuext21 and 3 previ-
ously reported apoA-II variants was compared using
bioinformatics methods. MetaserverAmylPred2.022,23
identiﬁed amyloidogenic segments with a high pro-
pensity to initiate apoA-II misfolding. Consistent with
previous studies, 2 hotspots located in residues 10 to 18
and 60 to 70 were present in all variants and the wild-
type protein (Figure 6a)18; a third hotspot was located
in the C-terminal extension of the variant proteins.
The hydrophobic Leu78 residue, positioned at the
edge of the C-terminal hotspot, was predicted to
increase the amyloid-forming propensity of the protein
and slightly extend it to residues 76 to 87 compared to
residues 79 to 87 in other variants (Figure 6a).
PASTA218,24,25 analysis of apoA-II 78Leuext21
variant showed 3 aggregation-prone segments with a
predicted aggregation energy below the threshold value
of -5 PASTA units (Figure 6b). Two of these segments,
residues 8 to 29 and 60 to 69, were located in class-A
amphipathic a-helices that comprise the native
structure of apoA-II on HDL and are proposed to
protect wild-type apoA-II from misfolding through
tight binding to HDL.18 An additional aggregation-
prone segment was predicted in residues 78 to 86 of
the C-terminal extension (Figure 6b). Three other
apoA-II variants showed similar results, but with
slightly lower aggregation propensity in the C-terminal
extension compared to 78Leuext21 variant (data not
shown). Compared to wild-type apoA-II, the C-
terminal extension of 78Leuext21 variant was less
likely to form an a-helix (Figure 6c) and much more
likely to adopt a b-sheet structure (Figure 6d); this was
also true of the other apoA-II variants (data not
shown). Moreover, amino acid sequence analysis
clearly showed that neither the a-helix nor b-sheet
structures formed by the C-terminal extension was
amphipathic, indicating that this domain has little if
any afﬁnity for HDL and, hence, is not protected from
misfolding by the bound lipids.
DISCUSSION
We describe a female patient of Filipino-Portuguese
descent with hereditary renal amyloidosis caused by a
novel heterozygous mutation in the translation termi-
nation codon of APOA2 that results in replacement of
the stop codon with leucine and expression of a variant
protein with a 21-amino acid residue C-terminus exten-
sion, apoA-II 78Leuext21. AApoAII amyloidosis was
ﬁrst reported in 2 sisters with nephropathy13; 28 years
later, renal amyloidosis was reported in 2 brothers
Figure 2. (Continued) (e) Partial sequence chromatogram of APOA2 exon 4. Black arrow indicates a single base transversion, c.302G>T, in the
translation termination codon encoding a replacement of the stop codon with a leucine residue at position 78 of the protein. The resulting
variant, apoA-II 78Leuext21, contains an extended C-terminal region composed of an additional 21 amino acid residues. Screening for mutations
in APOA1, TTR, LYZ, and FGA demonstrated no abnormalities.
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from the third generation of this family, and full-length
apoA-II 78Glyext21was identiﬁed as the ﬁbril
constituent in the amyloid deposits.14 In total, 4
heterozygous APOA2 stop codon mutations have been
described; all encoded protein variants that were
associated with renal amyloidosis (Table 1). The
78Argext21 variant has been detailed in Armenian and
Spanish males, each with family history of
nephropathy16,17; the 78Serext21 variant was reported
in a Caucasian male with no family history.15 In all
cases, disease manifested in the fourth and ﬁfth
decades of life (Table 1). Interestingly, renal
amyloidosis caused by wild-type apoA-II has been
reported in a Japanese male, but clinical symptoms
were not observed until the seventh decade.26
Similar to previous reports, the 78Leuext21 variant
featured renal disease characterized by nephrotic range
proteinuria and elevated creatinine with progression to
end-stage renal disease (ESRD). The time from diagnosis
to ESRD ranged from 3 years in the proband II-4 to 6
and 2 years in her affected children, III-1 and III-2,
respectively. A longer progression to ESRD, ranging
from 18 years in the proband to 8 and 12 years in 2
affected children, was noted in the 78Glyext21 series
(Table 1).27 Moreover, in AApoAII 78Argext21, the
patient had not reached ESRD after a 22-year course
of renal disease,16 suggesting that protein sequence,
speciﬁcally the amino acid at residue 78, is linked to
the rate of disease progression.
The ﬁrst case of successful renal transplantation
with stable graft function over 9-year follow-up was
reported in a patient with 78Glyext21 variant
(Table 1).27 In our cases II-4 and III-1, the graft remains
functioning 14 and 2 years posttransplantation. The
slow decline in renal function with microalbuminuria
in proband II-4 is likely caused by chronic allograft
nephropathy.
Indicators of amyloid cardiomyopathy as demon-
strated by EKG, echocardiography, and 99mTc-pyro-
phosphate scintigraphy were reported in a patient with
the 78Argext21 variant 20 years after the initial disease
presentation (Table 1).16 Another case of AApoAII-
associated cardiomyopathy has been reported recently;
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Figure 4. Immunoelectrophoretic analysis of kidney-extracted amy-
loid ﬁbrils. Amyloid ﬁbrils isolated from proband (II-4) kidney tissue
were analyzed by nonreducing (left side) and reducing (right side)
immunoelectrophoresis with monoclonal antihuman apoA-II anti-
body. The ﬁbril samples were run at 2 concentrations and compared
to proband serum results. From left to right, sample lanes in both
analyses contain serum (II-4S) and kidney-extracted amyloid ﬁbrils
(1:10 dilution, II-4f; undiluted, II-4F) from the proband, and puriﬁed
wild-type apoA-II protein (C-3). Abbreviations denote assignments
from proband serum analysis (II-4S lane): VþV, variant apoA-II
homodimer; WTþV, wild-type and variant apoA-II heterodimer;
WTþWT, wild-type apoA-II homodimer. *Indicates bands excised
for mass spectral analyses. The presence of an immunoreactive
band with a molecular weight of 21 kDa under reducing conditions
suggests incomplete reduction of the apoA-II variant homodimer.
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Figure 3. Serum immunoelectrophoretic testing with monoclonal
antihuman apoA-II antibody. A-II proteins in sera from affected and
unaffected family members, and controls were analyzed by immu-
noelectrophoresis under (a) nonreducing and (b) reducing condi-
tions. In both gels, lanes were loaded from left to right with sera from
the proband (II-4), her daughter (III-1) and son (III-2), nonaffected
family members (II-1 and II-3), and several controls; C-1 represents
positive control serum from a patient with AApoAII 78Glyext21
amyloidosis; C-2 represents healthy control serum; and C-3 is puriﬁed
wild-type apoA-II protein. The bottom panel in (a) shows an
enhanced view of the lower region of the blot obtained with an
extended exposure time. V, variant apoA-II monomer; WT, wild-type
apoA-II monomer; VþV, WTþV, and WTþWT, apoA-II dimers.
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however, neither clinical nor genetic information was
provided.28 Although no clinical evidence of
extrarenal involvement was demonstrated in our or
other reports of AApoAII amyloidosis,14,15,26,27
extrarenal amyloid deposits were found either
accidentally or at postmortem evaluation (Table 2).
Autopsy results from the 78Glyext21 series revealed
modest deposits in multiple organs from 2 individuals.13
In all cases of AApoAII amyloidosis, the amyloid
was located predominantly in the glomeruli,
with modest deposition noted in a few blood vessels
and rare peritubular deposits (Table 2).
Immunohistochemistry with antihuman apoA-II
antibody demonstrated positive glomerular staining
that colocalized with the amyloid deposits. A similar
pattern of renal amyloid distribution conﬁned to the
glomeruli is featured in ﬁbrinogen A-a chain
amyloidosis,6,29 whereas the glomerular compartment
is spared in apoA-IV and leukocyte chemotactic
factor 2 amyloidoses.29
Figure 5. Proteomic study of kidney-derived amyloid ﬁbrils using mass spectrometry. (a) Scaffold readout of the top 30 proteins identiﬁed in
excised gel slices containing 6 kDa, 8 kDa, and 10 kDa apoA-II ﬁbril proteins (Figure 4, asterisk [*]). The number in the box denotes the number
of spectra obtained on each sample for each identified protein. Green highlighting denotes >95% probability for protein identification. ApoA-II is
designated with a blue star and occurs as the #2 entry on the list; data show high abundance of the apoA-II in each sample, and the >95%
probability suggests strong confidence in the accuracy of the data. Universal amyloid tissue biomarker proteins, apolipoprotein E, and serum
amyloid P-component are each designated with an orange star and detected in all 3 samples; apolipoprotein A-IV is also detected at low levels
(#56 entry on scaffold readout table) and is not shown. Peptides representing several other amyloid-forming proteins, transthyretin, lysozyme C,
Ig k light chain, and Ig heavy chain were detected in low amounts; there was no evidence of other known amyloidogenic precursor proteins
associated with renal amyloidosis. (b) ApoA-II sequence coverage demonstrated in the 6 kDa, 8 kDa, and 10 kDa proteins. Peptides accounting
for 100% of the variant ApoA-II sequence (shown on yellow background) are identified in the 6-kDa and 10-kDa samples; 93% sequence
coverage is obtained in the 8-kDa sample; the peptide FQTVTDY, indicated with black triangles, is not detected. The proapoA-II peptide,
ALVRR (shown on white background), is not detected in any of the samples. The C-terminal extension sequence of variant apoA-II,
LSVQTIVFQPQLASRTPTGQS, is underlined. Residues, highlighted in green, denote artifactual modifications (pyro glutamic acid formation of
N-terminal glutamine or oxidation of methionine, correspondingly) induced by sample processing.
RESEARCH LETTERS
1228 Kidney International Reports (2017) 2, 1219–1232
An intriguing histological feature in the proband II-4
was the presence of numerous GCs located adjacent to
the glomerular amyloid deposits. Similar ﬁndings were
originally described in 2 siblings with AApoAII
78Glyext2113; however, no GCs were observed in the
current case III-1 or in other reports (Table 2).
Multinucleated GCs are frequently found in localized30
and, occasionally, systemic amyloidoses.31,32 Resulting
from the fusion of macrophages, GCs are considered to
function as phagocytes in the resorption of amyloid
deposits, but rarely succeed in the spontaneous
clearance of the ﬁbrils.33
Consistent with the heterozygous nature of the
APOA2 stop codon mutation, both wild-type and
variant apoA-II proteins were found in sera from
affected members in our study. Multiple dimeric forms
of apoA-II most likely representing the wild-type
homodimer, wild-type and variant heterodimer, and
variant homodimer were detected in the samples.14–16
Similar to other reports, the reduction of dimeric
apoA-II yielded wild-type and variant monomers with
molecular weights of approximately 8 and 10 kDa.
The nonvariant protein in serum from affected
member III-1 exhibited a slightly higher size compared
to wild-type bands identiﬁed in other affected members
II-4 and III-2 (Figure 3a, b). The increased molecular
weight, presumably, of the wild-type protein, may be
due to the presence of proapoA-II, a mature form of
the protein with a 5-residue pro-peptide (Figure 5b). A
small quantity of proapoA-II has been reported in
human circulation,34 and the intact proapoA-II was
found in amyloid deposits from a senescence
accelerated mouse model of aging.35 Nonetheless, there
is no report of proapoA-II deposition in AApoAII
amyloidosis and we have no evidence to support this
speculation as amyloid ﬁbril material was not available
for analysis on this case.
Immunoelectrophoretic analysis of amyloid ﬁbrils
from the proband II-2 showed multiple monomeric and
dimeric apoA-II species. Three bands with molecular
weights of 6, 8, and 10 kDa consistent with monomeric
apoA-II were subjected to mass spectral analysis. Each
sample demonstrated peptides that covered the entire
21-residue C-terminal extension of variant apoA-II and
essentially yielded full-length protein coverage. The
mass spectral data suggest that the entire 78Leuext21
variant is a major constituent of amyloid deposits in the
proband. These results are in agreement with previous
studies that reported full-length monomeric
78Argext21 and 78Glyext21 variants as major compo-
nents of amyloid deposits.14,16 The presence of the
variant apoA-II homodimer in the deposits of our
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78Leuext21   QAKEPCVESL VSQYFQTVTD  YGKDLMEKVK  SPELQAEAKS  YFEKSKEQLT PLIKKAGTEL  VNFLSYFVEL  GTQPATQLSV QTIVFQPQLA  SRTPTGQS
78Argext21   QAKEPCVESL VSQYFQTVTD  YGKDLMEKVK  SPELQAEAKS  YFEKSKEQLT  PLIKKAGTEL VNFLSYFVEL GTQPATQRSV QTIVFQPQLA  SRTPTGQS
78Serext21   QAKEPCVESL VSQYFQTVTD  YGKDLMEKVK  SPELQAEAKS  YFEKSKEQLT  PLIKKAGTEL VNFLSYFVEL GTQPATQSSV QTIVFQPQLA  SRTPTGQS
78Glyext21   QAKEPCVESL VSQYFQTVTD  YGKDLMEKVK  SPELQAEAKS  YFEKSKEQLT  PLIKKAGTEL VNFLSYFVEL GTQPATQGSV QTIVFQPQLA  SRTPTGQS
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b c d
Figure 6. In silico predictions of ApoA-II aggregation and secondary structure propensities. (a) Prediction of amyloid-forming hotspots is
accomplished using the consensus meta-server AmylPred2.22,23 The amino acid sequences of wild-type and amyloidogenic apoA-II variants are
shown. Residues 1 to 77 correspond to wild-type apoA-II, and residues 78 to 98 represent the C-terminal extensions of variant proteins; the
signal peptide is not included. The different residues located at position 78 in the apoA-II variants are shown in underscored bold and indicated
with black arrow. Amyloidogenic residue segments predicted by a consensus of at least 5 of 11 methods are shown in red italics. (b) Prediction
of aggregation propensity is accomplished using the sequence-based bioinformatics program PASTA2.018,24,25; the results are plotted as a
function of the residue number. Aggregation-free energy is shown in PASTA units (1 unit ¼ 1.192 kcal/mol).25 Favorable free energy that
exceeds the threshold of 5 PASTA units is indicated by a gray horizontal line. High aggregation propensity is predicted for residue
segments 8 to 29, 60 to 69, and 78 to 86. (c) a-Helix probability. (d) b-Strand probability. b-Strand probability is shown in black line, and
amyloidogenic propensity is shown in gray.
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patient suggests that ﬁbril formation does not neces-
sarily occur after apoA-II dimer reduction as previ-
ously hypothesized.14 The nature of the less abundant
dimeric apoA-II forms remains unclear. Although these
bands occurred at positions corresponding to wild-type
apoA-II dimer, our data neither conﬁrm nor refute the
Table 2. Histological features and biochemical characteristics of amyloid ﬁbrils in cases with AApoAII amyloidosis
Characteristic
78Leuext21
current report
78Argext21
78Serext2115 78Glyext2113,14,27 78Ter26
Ref16 Ref17
Kidney amyloid deposits II-4: Marked GM; small vascular
III-1: Marked GM
GM; vascular Present GM; vascular II.2: Marked GM; small
peritubular and vascular
II.4: Marked GM; small peritubular
and vascular
III.2: GM; small vascular
GM
Multinucleated giant cells II-4: GM
III-1: None
None None None II.2: GM
II.4: Around tubules
III.1: None
III.2: None
None
Extrarenal amyloid deposits II-4, III-2: Fat Skin and rectum:
vascular
None Fat and bone
marrow: vascular
II.2: Adrenal gland, liver, spleen,
heart, pancreas, GI, pituitary
II.4: Adrenal, liver, spleen, heart,
pancreas
III.2a
None
Kidney: IHC with apoA-II antibody GM staining Not done Not done Not done Not done GM staining
Amyloid deposits characterization II-4: Full-length apoA-II variantb ApoA-II variantc Not done Not done III.2: Full-length apoA-II variantd14 Not done
II-4, III-1, and III-2 indicate the proband and her affected children described in current report. II.2 and II.4, (reference13), III.1 and III.2 (references14,27) indicate probands and affected
family members with 78Glyext21 variant. GI, gastrointestinal; GM, glomerular; IHC, immunochistochemistry.
aAdrenal gland, liver, spleen, heart, and thyroid gland tissues were negative for amyloid deposits.
bConfirmed by mass spectral analysis.
cConfirmed by western blot analysis.
dConfirmed by western blot and Edman degradation analyses.
Table 1. Genetic, demographic, and clinical characteristics of cases with AApoAII amyloidosis
Characteristic
78Leuext21
current report
78Argext21
78Serext2115 78Glyext2113,14,27 78Ter26
Ref16 Ref17
Sequence variant (mRNA) c.302G>T c.301T>C c.301T>A c.302G>C c.301T>G c.¼
Ethnicity Filipino-Portuguese Armenian Spanish Caucasian American Japanese
Proband: age at disease onset, yr; gender II-4: 41F 34M No data M 42M II.2: 33F
II.4: 42F
67M
Affected family members: age at disease onset, yr; gender III-1: 30F
III-2: 33M
a b None III.1: Late 20thM
III.2: 34M
None
Renal involvement þ þ þ þ þ þ
24-h proteinuria at initial evaluation, g II-4: 13
III-1: 2.7
III-2: 7.4
3 No data 0.6 II.2: 3.3
II.4: no data
III.1: no data
III.2: no data
6.1
Time from ﬁrst symptom to ESRD, yr II-4: 3
III-1: 6
III-2: 2
c d c II.2: 18
II.4:d
III.1: 8
III.2: 12
c
Kidney transplant II-4: þ
III-1: þ
III-2: wait list
None Wait list None II.2: þ
II.4: þ
III.1: þ
III.2: þ,þ
None
Posttransplantation follow-up, yr II-4: 14
III-1: 2
– – – II.2: acute graft rejection
III.1: 9
III.2: acute graft rejection
–
Extrarenal involvement None Cardiac None None None None
Disease duration: ﬁrst symptom to the end of observation, yr II-4: 19
III-1: 11
III-2: 3
22 No data 4 II.2: 19
II.4: 5
III.1: 22
III.2: 17
3
Cause of death – – – – II.2: Klebsiella pneumonia
II.4: Renal failure
III.2: Sepsis
–
II-4, III-1, and III-2 indicate the proband and her affected children described in current report. II.2 and II.4, (reference13), III.1 and III.2 (references14,27) indicate probands and affected
family members with 78Glyext21 variant. F, female; M, male; ESRD, end-stage renal disease.
aFather of the proband, 53 years old, died of renal failure; a parental half-brother, 45 years old has renal failure.
bFour sisters and a nephew of the proband feature nephropathy.
cESRD was not reached at the end of follow-up observation.
dESRD was reached at the end of follow-up observation.
RESEARCH LETTERS
1230 Kidney International Reports (2017) 2, 1219–1232
presence of the wild-type protein in the deposits. It is
possible that these are truncated forms of dimeric
variant apoA-II.
Although all apoA-II variants were predicted to
have similar amyloid hotspots, the segment located in
the C-terminal extension of apoA-II 78Leuext21 had a
slightly higher aggregation propensity than other
mutants, likely due to the highly hydrophobic nature
of leucine (Figure 6). We speculate that the increased
hydrophobicity of leucine-containing C-terminal
extension may contribute to more rapid progression
to ESRD compared to other variants (Table 1).
Moreover, the C-terminal extension of the
78Leuext21variant was also predicted to have a
greatly increased propensity to form b-sheet and
lower a-helical propensity compared to the rest of
the apoA-II molecule (Figure 6c, d). Importantly,
neither the b-strand nor the a-helix formed by the C-
terminal extension is amphipathic. Therefore, unlike
the rest of the apoA-II molecule, the amyloid hotspot
located in the C-terminal extension is not protected
from aggregation and is likely to trigger the release of
apoA-II from HDL and initiate protein misfolding
from the highly helical native conformation on HDL
to the intermolecular b-sheet in amyloid.
In conclusion, we report a kinship with AF renal
amyloidosis caused by a novel apoA-II 78Leuext21
variant. The disease is characterized by renal
dysfunction progressing to ESRD due to glomerular
amyloid deposits comprising full-length apoA-II
variant. A segment of the variant protein located
within the leucine-containing C-terminal extension is
predicted to have a slightly higher aggregation pro-
pensity compared to other amyloidogenic variants and
may contribute to more rapid progression of kidney
disease. The study indicates that AApoAII amyloidosis
should be considered in the differential diagnosis of
patients with hereditary renal disease.
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